Pulmonx to Report Fourth Quarter and Full Year 2025 Financial Results on March 4, 2026

Core Viewpoint - Pulmonx Corporation is set to release its financial results for Q4 and the full year of 2025 on March 4, 2026, with a conference call scheduled to discuss these results [1]. Company Overview - Pulmonx Corporation (Nasdaq: LUNG) is recognized as a global leader in minimally invasive treatments for chronic obstructive pulmonary disease (COPD) [3]. - The company’s key products include the Zephyr Endobronchial Valve, Chartis Pulmonary Assessment System, LungTraX™ Platform, and StratX Lung Analysis Reports, which are aimed at treating patients with severe emphysema/COPD [3]. - The Zephyr Valve has received FDA pre-market approval as a "breakthrough device" and is available in over 25 countries, being included in global treatment guidelines as a standard care option for improving patient outcomes [3].